ES2542227T3 - Tratamiento de complicaciones vasculares de diabetes - Google Patents

Tratamiento de complicaciones vasculares de diabetes Download PDF

Info

Publication number
ES2542227T3
ES2542227T3 ES10166637.8T ES10166637T ES2542227T3 ES 2542227 T3 ES2542227 T3 ES 2542227T3 ES 10166637 T ES10166637 T ES 10166637T ES 2542227 T3 ES2542227 T3 ES 2542227T3
Authority
ES
Spain
Prior art keywords
diabetes
treatment
vascular complications
natural
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10166637.8T
Other languages
English (en)
Inventor
Bernhard Fischer
Rudolf Lucas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apeptico Forschung und Entwicklung GmbH
Original Assignee
Apeptico Forschung und Entwicklung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeptico Forschung und Entwicklung GmbH filed Critical Apeptico Forschung und Entwicklung GmbH
Application granted granted Critical
Publication of ES2542227T3 publication Critical patent/ES2542227T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Péptido que consiste en 7-17 aminoácidos e incluye el hexámero TX1EX2X3E, en la que X1, X2 y X3 pueden ser cualquier aminoácido natural o no natural, en el que el péptido no muestra actividad de unión al receptor de TNF y es cíclico, para su uso en el tratamiento o la prevención de complicaciones vasculares en pacientes con diabetes.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES10166637.8T 2010-06-21 2010-06-21 Tratamiento de complicaciones vasculares de diabetes Active ES2542227T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20100166637 EP2397151B1 (en) 2010-06-21 2010-06-21 Treatment of vascular complications of diabetes

Publications (1)

Publication Number Publication Date
ES2542227T3 true ES2542227T3 (es) 2015-08-03

Family

ID=42562567

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10166637.8T Active ES2542227T3 (es) 2010-06-21 2010-06-21 Tratamiento de complicaciones vasculares de diabetes
ES10771018T Active ES2933405T3 (es) 2010-06-21 2010-10-20 Tratamiento de complicaciones vasculares de diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10771018T Active ES2933405T3 (es) 2010-06-21 2010-10-20 Tratamiento de complicaciones vasculares de diabetes

Country Status (14)

Country Link
US (1) US9359419B2 (es)
EP (2) EP2397151B1 (es)
JP (1) JP5878922B2 (es)
KR (1) KR101752260B1 (es)
CN (1) CN102946897B (es)
AU (1) AU2010355825B9 (es)
BR (1) BR112012033045A2 (es)
CA (1) CA2800261C (es)
DK (1) DK2397151T3 (es)
ES (2) ES2542227T3 (es)
MX (1) MX2012014195A (es)
PL (1) PL2397151T3 (es)
RU (1) RU2545718C2 (es)
WO (1) WO2011160664A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
AU2014257678A1 (en) * 2013-04-23 2015-10-15 Apeptico Forschung Und Entwicklung Gmbh Lyophilisate containing a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2
ES2791225T3 (es) * 2014-03-04 2020-11-03 Apeptico Forschung & Entwicklung Gmbh Atenuación de la inflamación intrapulmonar
AU2015233635B2 (en) * 2014-03-18 2019-07-25 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
JP2023525522A (ja) 2020-05-08 2023-06-16 アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃｏｖｉｄ－１９の治療または予防用ペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69938743D1 (de) * 1998-08-14 2008-06-26 Rudolf Lucas TNF-Peptide zur Behandlung von Ödemen
US8236750B2 (en) 2004-08-06 2012-08-07 Nycomed Gmbh Composition comprising a pulmonary surfactant and a TNF-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität

Also Published As

Publication number Publication date
CN102946897A (zh) 2013-02-27
RU2545718C2 (ru) 2015-04-10
CN102946897B (zh) 2017-12-12
RU2013102344A (ru) 2014-07-27
BR112012033045A2 (pt) 2017-06-20
AU2010355825B2 (en) 2014-10-16
JP5878922B2 (ja) 2016-03-08
MX2012014195A (es) 2013-02-07
KR20130127359A (ko) 2013-11-22
CA2800261A1 (en) 2011-12-29
EP2582385B1 (en) 2022-11-16
PL2397151T3 (pl) 2015-10-30
EP2397151B1 (en) 2015-04-22
US9359419B2 (en) 2016-06-07
KR101752260B1 (ko) 2017-06-29
DK2397151T3 (en) 2015-05-18
EP2397151A1 (en) 2011-12-21
US20130116200A1 (en) 2013-05-09
JP2013530970A (ja) 2013-08-01
CA2800261C (en) 2018-01-02
ES2933405T3 (es) 2023-02-08
AU2010355825A1 (en) 2013-01-31
WO2011160664A1 (en) 2011-12-29
AU2010355825B9 (en) 2015-02-05
EP2582385A1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2542227T3 (es) Tratamiento de complicaciones vasculares de diabetes
CO2020009625A2 (es) Inhibidor de fap
ES2525758T3 (es) Composición que comprende un péptido y un inhibidor de la neuraminidasa vírica
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
ES2575397T3 (es) Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
CY1121042T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
ES2494316T3 (es) Ingrediente activo novedoso en cicatrización y uso del mismo
RU2015149010A (ru) Биологические маркеры, которые могут быть использованы в иммунотерапии рака
ES2650463T3 (es) Tratamiento de enfermedades inflamatorias con ACE2
CL2012002031A1 (es) Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente.
EA201391756A1 (ru) Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
ES2513392T3 (es) Materiales biológicos y usos de los mismos
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
BRPI0814097A8 (pt) Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
EA201500061A1 (ru) Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением
CL2012001656A1 (es) Polipéptido de somatotropina bovina que comprende uno o mas aminoácidos no naturales y que estan ligados a un polimero soluble en agua. composicion farmaceutica que comprende dichos polipeptidos.
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
BRPI0917656A2 (pt) Fatores viii e ix humanos produzidos de forma recombinante
ES2545614T3 (es) Proteínas truncadas con nudo de cistina